- 메인이동
- 보고서
주요 국가별 의료집적단지 조사 및 분석보고서
등록일 2023-02-03제1장 연구개요 ····································································································································1
1. 연구 배경 및 필요성 ················································································································3
2. 연구목적 및 내용 ·····················································································································5
3. 사례조사 대상 ···························································································································6
4. 사례조사 항목 및 방법 ············································································································7
제2장 바이오클러스터 사례조사 ········································································································9
1. 아시아 ·····································································································································11
1.1 중국 베이징 중관춘생명과학단지 (Zhongguancun Life Science Park) ··············11
1.2 중국 상하이 장지앙파마벨리(Zhangjiang Pharma Valley) ····································17
1.3 일본 고베 의료산업도시 (Kobe Biomedical Innovation Cluster; KBIC) ··········23
1.4 싱가포르 Tuas Biomedical Park ··············································································29
1.5 싱가포르 바이오폴리스(Biopolis) ················································································35
2. 북미 ·········································································································································43
2.1 미국 노스캐롤라이나 리서치트라이앵글파크(Research Triangle Park; RTP) ······43
2.2 미국 샌디에고 Life Science Cluster ·········································································50
2.3 미국 텍사스 메디컬센터 (Texas Medical Center) ··················································57
2.4 미국 보스턴 Boston Biotech Cluster ·······································································63
2.5 미국 샌프란시스코 Bay area Biocluster ··································································71
2.6 미국 BioHealth Capital Region (BHCR) ·······························································77
2.7 캐나다 토론토 Medical and Related Sciences (MaRS) Discovery District ····82
3. 유럽 ·········································································································································89
3.1 영국 Cambridge Science Park ················································································89
3.2 스웨덴 Stockholm-Uppsala Life Science Park ····················································94
3.3 독일 베를린-브란덴부르크 HealthCapital (Cluster Healthcare Industries
Berlin-Brandenburg) ································································································100
3.4 독일 라인-네카 지역 생명과학 클러스터 (Life Science Cluster Rhine-Neckar;
BioRN) ·························································································································107
3.5 프랑스 파리 Station F ·······························································································113
3.6 덴마크-스웨덴 Medicon Valley ···············································································118
3.7 스위스-프랑스-독일 BioValley Life Science Cluster ··········································123
3.8 벨기에 바이오클러스터 ································································································128
4. 오세아니아 ····························································································································134
4.1 호주 멜버른 Melbourne Biomedical Precinct (MBP) ········································134
제3장 사례조사 결과 분석 ·············································································································141
1. 조사 대상의 주요 특징 ·······································································································143
1.1 설립 배경에 따른 분류 (정부주도형, 민간주도형) ····················································143
1.2 클러스터 형태에 따른 구분 ························································································145
1.3 대형병원이 혁신 활동에 큰 역할을 하는 클러스터 ··················································146
2. 바이오클러스터 성공 요인 도출 ·························································································149